EP4357362A4 - Bispezifische antikörperkombination und verwendung davon - Google Patents

Bispezifische antikörperkombination und verwendung davon

Info

Publication number
EP4357362A4
EP4357362A4 EP22824340.8A EP22824340A EP4357362A4 EP 4357362 A4 EP4357362 A4 EP 4357362A4 EP 22824340 A EP22824340 A EP 22824340A EP 4357362 A4 EP4357362 A4 EP 4357362A4
Authority
EP
European Patent Office
Prior art keywords
bispecific antibody
antibody combination
combination
bispecific
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22824340.8A
Other languages
English (en)
French (fr)
Other versions
EP4357362A1 (de
Inventor
Xiaodong Wu
Chen Zhong
Fangfang Du
Gezi Jia
Yongqiang Wang
Lei Shi
Yun He
Yiping Rong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbour Biomed Shanghai Co Ltd
Original Assignee
Harbour Biomed Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbour Biomed Shanghai Co Ltd filed Critical Harbour Biomed Shanghai Co Ltd
Publication of EP4357362A1 publication Critical patent/EP4357362A1/de
Publication of EP4357362A4 publication Critical patent/EP4357362A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP22824340.8A 2021-06-18 2022-06-17 Bispezifische antikörperkombination und verwendung davon Pending EP4357362A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110678326 2021-06-18
CN202210634042 2022-06-06
PCT/CN2022/099607 WO2022262868A1 (zh) 2021-06-18 2022-06-17 一种双抗组合及其应用

Publications (2)

Publication Number Publication Date
EP4357362A1 EP4357362A1 (de) 2024-04-24
EP4357362A4 true EP4357362A4 (de) 2025-10-22

Family

ID=84526898

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22824340.8A Pending EP4357362A4 (de) 2021-06-18 2022-06-17 Bispezifische antikörperkombination und verwendung davon

Country Status (9)

Country Link
US (1) US20250326843A1 (de)
EP (1) EP4357362A4 (de)
JP (1) JP2024523415A (de)
KR (1) KR20240022613A (de)
CN (1) CN117500833A (de)
AU (1) AU2022291982A1 (de)
CA (1) CA3223103A1 (de)
TW (1) TWI833244B (de)
WO (1) WO2022262868A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022002012A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 抗b7h4抗体及其双抗和应用
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
US20250136694A1 (en) * 2021-08-18 2025-05-01 Harbour Biomed (Shanghai) Co., Ltd Anti-b7-h4 antibody, and preparation method therefor and use thereof
GB202402048D0 (en) * 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
KR20250148506A (ko) 2024-04-04 2025-10-14 주식회사 크로스포인트테라퓨틱스 인간 항체 Fc 변이체 포함 이중항체 및 그 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019005640A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
CN115698088A (zh) * 2020-06-30 2023-02-03 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
TWI815136B (zh) * 2020-06-30 2023-09-11 大陸商和鉑醫藥（上海）有限責任公司 一種雙特異性抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019005640A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BACAC MARINA: "CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies", 1 December 2016 (2016-12-01), XP055597693, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/128/22/1836?sso-checked=true> [retrieved on 20190618], DOI: 10.1182/blood.V128.22.1836.1836 *
BAO MUSHENG ET AL: "Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecifics for Solid Tumor Therapies HBM Holdings Limited", 11 September 2022 (2022-09-11), pages 1 - 40, XP093311691, Retrieved from the Internet <URL:www.harbourbiomed.com/upload/files/202210191155013408.pdf> [retrieved on 20250904] *
CHRISTINA CLAUS ET AL: "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy", SCIENCE TRANSLATIONAL MEDICINE, vol. 11, no. 496, 12 June 2019 (2019-06-12), pages eaav5989, XP055722436, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aav5989 *
GREGORY L. MOORE ET AL: "A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats", METHODS, vol. 154, 1 February 2019 (2019-02-01), NL, pages 38 - 50, XP055625796, ISSN: 1046-2023, DOI: 10.1016/j.ymeth.2018.10.006 *
IIZUKA AKIRA ET AL: "A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer", CLINICAL CANCER RESEARCH, vol. 25, no. 9, 1 May 2019 (2019-05-01), pages 2925 - 2934, XP055811280, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-3123 *
MARLONJ HINNER ET AL: "Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 2, 4 November 2015 (2015-11-04), pages 1, XP021235241, DOI: 10.1186/2051-1426-3-S2-P187 *
See also references of WO2022262868A1 *
TODD BARTKOWIAK ET AL: "4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity", FRONTIERS IN ONCOLOGY, vol. 5, 8 June 2015 (2015-06-08), pages 1 - 16, XP055498974, DOI: 10.3389/fonc.2015.00117 *
YOU GIHOON ET AL: "B7-H3x4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 + tumor-infiltrating lymphocytes", SCIENCE ADVANCES, vol. 7, no. 3, 15 January 2021 (2021-01-15), XP055879163, DOI: 10.1126/sciadv.aax3160 *
YU SHENGNAN ET AL: "A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 38, no. 1, 14 August 2019 (2019-08-14), XP055923522, Retrieved from the Internet <URL:https://jeccr.biomedcentral.com/track/pdf/10.1186/s13046-019-1354-1.pdf> DOI: 10.1186/s13046-019-1354-1 *

Also Published As

Publication number Publication date
EP4357362A1 (de) 2024-04-24
CN117500833A (zh) 2024-02-02
TWI833244B (zh) 2024-02-21
KR20240022613A (ko) 2024-02-20
US20250326843A1 (en) 2025-10-23
JP2024523415A (ja) 2024-06-28
AU2022291982A1 (en) 2024-02-01
TW202302651A (zh) 2023-01-16
CA3223103A1 (en) 2022-12-22
WO2022262868A1 (zh) 2022-12-22

Similar Documents

Publication Publication Date Title
EP4169948A4 (de) Anti-cd73-antikörper und verwendung davon
EP4159763A4 (de) Anti-cd73-antikörper und verwendung davon
EP4095148A4 (de) Anti-trop-2-antikörper-exatecan-analog-konjugat und medizinische verwendung davon
EP4251652A4 (de) Cldn18.2-antikörper und verwendung davon
EP4141033A4 (de) Anti-cd73-anti-pd-1-bispezifischer antikörper und verwendung davon
EP3907240A4 (de) Anti-tnfr2-antikörper und verwendung davon
EP4039707A4 (de) Zielgerichteter cd3-antikörper, bispezifischer antikörper und verwendung davon
EP4234580A4 (de) Auf nkg2a abzielender antikörper und verwendung davon
EP3854816A4 (de) Anti-b7h3-antikörper-exatecan-analog-konjugat und seine medizinische verwendung
MA52390A (fr) Anticorps anti-coronavirus et procédés d&#39;utilisation
EP4261223A4 (de) Anti-sirp? antikörper und anwendung davon
EP3988573A4 (de) Anti-cd3e/bcma-bispezifische antikörper und verwendung davon
EP3999545A4 (de) Anti-cd73-antikörper und verwendung davon
EP4095160A4 (de) Anti-st2-antikörper und verwendung davon
EP3819313A4 (de) Bispezifischer antikörper und verwendung davon
EP4082570A4 (de) Anti-ctla-4-antikörper und verwendung davon
EP4289862A4 (de) Anti-human-b7-h3-antikörper und anwendung davon
EP4371980A4 (de) Aak1-inhibitor und verwendung davon
EP4397683A4 (de) Monoklonaler anti-humaner interleukin-33-antikörper und verwendung davon
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d&#39;utilisation
EP4273166A4 (de) Anti-fgfr2-antikörper und verwendung davon
EP4446344A4 (de) Anti-cd24-antikörper und verwendung davon
EP4163300A4 (de) Gfral-antagonistischer antikörper und dessen verwendung
EP4036113A4 (de) Humanisierter anti-il17a-antikörper und verwendung davon
EP4086287A4 (de) Anti-claudin-18.2-antikörper und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250923

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20250917BHEP

Ipc: A61K 39/395 20060101ALI20250917BHEP

Ipc: A61P 35/00 20060101ALI20250917BHEP

Ipc: C12N 5/0783 20100101ALI20250917BHEP

Ipc: C12N 15/09 20060101ALI20250917BHEP

Ipc: C07K 16/32 20060101ALI20250917BHEP